BIOMAT Database Logo BIOMAT Database Logo

Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients. 1979

O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak

Furosemide and hydrochlorothiazide were compared for treatment of black patients with mild to moderate hypertension in a randomized, open-label, crossover study design. Hydrochlorothiazide produced a significantly greater fall in mean arterial (24.7 vs 16.0 mm Hg, P less than .01) and diastolic (17.3 vs 10.1 mm Hg, P less than .01) blood pressure (BP) in 16 patients. Addition of methyldopa in nine patients produced a significantly greater fall in mean arterial (38.8 vs 31.9 mm Hg, P less than .05) and diastolic (28.9 vs 23.4 mm Hg, P less than .05) BP with hydrochlorothiazide vs furosemide. Renin status was categorized before and after treatment. Patients with low and normal renin activity were equally responsive to both diuretics. Hydrochlorothiazide caused a greater reduction in plasma potassium (0.26 mEg/L). Serum parathyroid hormone was not chronically elevated with furosemide. In this study, hydrochlorothiazide was more effective than furosemide for treatment of mild to moderate hypertension in black patients; renin classification did not predict diuretic responsiveness.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001741 Black or African American A person having origins in any of the black racial groups of Africa (https://www.federalregister.gov/documents/1997/10/30/97-28653/revisions-to-the-standards-for-the classification-of-federal-data-on-race-and-ethnicity). In the United States it is used for classification of federal government data on race and ethnicity. Race and ethnicity terms are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. African American,African Americans,African-American,Afro-American,Afro-Americans,Black Americans,Blacks,Negroes,African-Americans,Negro,Afro American,Afro Americans,American, African,American, Black,Black American
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak
Antihypertensive effects of acebutolol plus hydrochlorothiazide and hydrochlorothiazide alone in black patients.
July 1986, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak
Antihypertensive therapy with diltiazem and comparison with hydrochlorothiazide.
June 1984, The American journal of cardiology,
O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak
Furosemide compared with hydrochlorothiazide.
January 1979, JAMA,
O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak
Antihypertensive therapy with nitrendipine: comparison with hydrochlorothiazide and propranolol.
January 1988, Journal of cardiovascular pharmacology,
O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak
Prazosin versus hydrochlorothiazide as initial antihypertensive therapy in black versus white patients.
January 1989, The American journal of medicine,
O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak
Clinical aspects of antihypertensive therapy with urapidil. Comparison with hydrochlorothiazide.
January 1990, Drugs,
O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak
Initial antihypertensive therapy. Comparison of prazosin and hydrochlorothiazide.
February 1986, The American journal of medicine,
O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak
Comparison of metoprolol as hydrochlorothiazide and antihypertensive agents.
January 1976, European journal of clinical pharmacology,
O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak
Clinical trial of a new diuretic, furosemide: comparison with hydrochlorothiazide and mercaptomerin.
December 1965, Canadian Medical Association journal,
O B Holland, and C E Gomez-Sanchez, and L V Kuhnert, and C Poindexter, and C Y Pak
Antihypertensive effects of low doses of hydrochlorothiazide in hypertensive black Zimbabweans.
November 1992, International journal of cardiology,
Copied contents to your clipboard!